Pam Wapnick serves as the Chief Financial Officer of Capsida.  She has more than 25 years of diversified financial experience, including financial planning, investor relations, controllership, treasury and M&A at both large multinational and startup companies. She served as Vice President and Treasurer at Amgen, where she raised more than $6 billion in capital markets financing and initiated a dividend.  She then served as Vice President of R&D finance at Amgen, where she led a team of more than 20 financial professionals through all aspects of short- and long-range financial forecasting and rebalancing of the R&D spend from mature to launch products. As Chief Financial Officer of True North Therapeutics, she executed a Series D financing and filed an S-1 with the SEC prior to the company being acquired for up to $825 million. As Chief Financial Officer of Graybug Vision, she led finance, human resources, information technology and facilities, and completed a Series C financing.

Ms. Wapnick holds a B.A. in economics from Wellesley College an M.B.A. in finance from Columbia University.